Adalimumab for psoriasis patients who are non‐responders to etanercept: open‐label prospective evaluation
Adalimumab for psoriasis patients who are non‐responders to etanercept: open‐label prospective evaluation
复制标题
阿达木单抗治疗对依那西普无反应的银屑病患者：开放标签前瞻性评估
DOI：
10.1111/j.1468-3083.2009.03325.x
复制
发表时间：
2009
影响因子：
9.2
通讯作者：
J. Barker
中科院分区：
文献类型：
--
作者：
C. Martyn;L. Green;G. Ash;R. Groves;C. Smith;J. Barker
背景 靶向生物疗法对中重度银屑病的治疗产生了重大影响。在英国，国家健康与临床卓越研究所推荐依那西普（一种人重组肿瘤坏死因子（TNF）受体融合蛋白）用于常规治疗失败的中度至重度银屑病患者。然而，尚无其他 TNF 拮抗剂对依那西普治疗失败的患者的作用的数据。阿达木单抗是一种全人源抗 TNF 单克隆抗体，被批准用于治疗中度至重度牛皮癣。
Background Targeted biologic therapies have made a significant impact on the treatment for moderate to severe psoriasis. In the United Kingdom, the National Institute for Health and Clinical Excellence recommends etanercept, a human recombinant tumour necrosis factor (TNF) receptor fusion protein, for moderate to severe psoriasis patients who have failed conventional therapies. There is, however, no data available on the role of other TNF antagonists for patients who have failed etanercept. Adalimumab, a fully human, anti‐TNF monoclonal antibody, is approved for treatment of moderate to severe psoriasis.
影响因子：
2.7
作者：
Nickoloff, Brian J.;Xin, Hong;Qin, Jian-Zhong
通讯作者：
Qin, Jian-Zhong